$318 Million is the total value of EcoR1 Capital, LLC's 31 reported holdings in Q4 2015. The portfolio turnover from Q3 2015 to Q4 2015 was 64.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| FGEN | Sell | FIBROGEN INC | $37,066,000 | +37.4% | 1,216,473 | -1.1% | 11.64% | -5.2% |
| FPRX | Buy | FIVE PRIME THERAPEUTICS INC | $29,839,000 | +1201.3% | 719,000 | +382.6% | 9.37% | +797.7% |
| New | JAZZ PHARMACEUTICALScall | $26,594,000 | – | 189,200 | +100.0% | 8.35% | – | |
| RTRX | Buy | RETROPHIN INC | $23,618,000 | +15.7% | 1,224,384 | +21.5% | 7.42% | -20.2% |
| Sell | ARRAY BIOPHARMA INCnote | $21,633,000 | -2.6% | 22,534 | -99.9% | 6.79% | -32.8% | |
| KURA | New | KURA ONCOLOGY INC | $20,580,000 | – | 2,450,000 | +100.0% | 6.46% | – |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $15,758,000 | -12.6% | 2,098,302 | +11.2% | 4.95% | -39.7% |
| CYTK | New | CYTOKINETICS INC | $14,840,000 | – | 1,418,700 | +100.0% | 4.66% | – |
| Buy | VALEANT PHARMACEUTICALS INTLcall | $12,859,000 | +854.6% | 126,500 | +9900.0% | 4.04% | +558.9% | |
| COLL | COLLEGIUM PHARMACEUTICAL INC | $12,791,000 | +24.4% | 465,118 | 0.0% | 4.02% | -14.2% | |
| EPZM | Sell | EPIZYME INC | $11,196,000 | -41.7% | 698,900 | -53.2% | 3.52% | -59.8% |
| GLPG | New | GALAPAGOSsponsored adr | $10,524,000 | – | 167,361 | +100.0% | 3.30% | – |
| KITE | Sell | KITE PHARMA INC | $10,229,000 | -34.7% | 166,000 | -41.0% | 3.21% | -54.9% |
| FLKS | Sell | FLEX PHARMA INC | $9,899,000 | -11.7% | 795,088 | -14.8% | 3.11% | -39.1% |
| IRWD | New | IRONWOOD PHARMACEUTICALS | $9,522,000 | – | 821,531 | +100.0% | 2.99% | – |
| NBRV | Buy | NABRIVA THERAPEUTICS AGsponsored adr | $7,931,000 | -0.1% | 838,680 | +0.4% | 2.49% | -31.1% |
| LIFE | Sell | ATYR PHARMA INC | $7,770,000 | -9.9% | 790,462 | -5.9% | 2.44% | -37.8% |
| KIN | Buy | KINDRED BIOSCIENCES INC | $4,871,000 | -29.2% | 1,432,765 | +8.3% | 1.53% | -51.1% |
| New | RETROPHIN INCcall | $4,709,000 | – | 244,100 | +100.0% | 1.48% | – | |
| CLDN | CELLADON CORP | $4,179,000 | +40.0% | 2,843,170 | 0.0% | 1.31% | -3.4% | |
| OVAS | New | OVASCIENCE INC | $4,152,000 | – | 424,979 | +100.0% | 1.30% | – |
| GNVC | Sell | GENVEC INC | $3,534,000 | -23.0% | 1,920,913 | -3.3% | 1.11% | -46.9% |
| CALA | CALITHERA BIOSCIENCES INC | $3,183,000 | +41.1% | 415,480 | 0.0% | 1.00% | -2.6% | |
| New | CYTOKINETICS INCcall | $2,977,000 | – | 284,600 | +100.0% | 0.94% | – | |
| ZFGN | New | ZAFGEN INC | $2,321,000 | – | 369,000 | +100.0% | 0.73% | – |
| FWP | Sell | FORWARD PHARMA A/Ssponsored adr | $1,900,000 | -20.9% | 100,017 | -1.9% | 0.60% | -45.4% |
| AKTX | Buy | AKARI THERAPEUTICS PLCsponsored adr | $1,461,000 | -39.6% | 100,750 | +0.0% | 0.46% | -58.3% |
| Buy | GILEAD SCIENCES INCcall | $1,194,000 | -44.4% | 11,800 | +262.5% | 0.38% | -61.7% | |
| NRXGQ | New | NEPHROGENEX INC | $941,000 | – | 588,235 | +100.0% | 0.30% | – |
| QLTI | Sell | QLT INC | $266,000 | -84.3% | 100,000 | -84.3% | 0.08% | -89.1% |
| New | ZAFGEN INCcall | $63,000 | – | 10,000 | +100.0% | 0.02% | – | |
| Exit | REGULUS THERAPEUTICS INCcall | $0 | – | -1,280 | -100.0% | -0.02% | – | |
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -56,000 | -100.0% | -0.12% | – |
| OREX | Exit | OREXIGEN THERAPEUTICS INC | $0 | – | -937,958 | -100.0% | -0.90% | – |
| ONTY | Exit | ONCOTHYREON INC | $0 | – | -943,500 | -100.0% | -1.18% | – |
| ATRA | Exit | ATARA BIOTHERAPEUTICS INC | $0 | – | -803,458 | -100.0% | -11.50% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2016-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| KURA ONCOLOGY ORD | 32 | Q3 2023 | 10.5% |
| XENCOR ORD | 25 | Q3 2023 | 12.6% |
| ASSEMBLY BIOSCIENCES ORD | 23 | Q3 2020 | 19.0% |
| FIBROGEN ORD | 22 | Q1 2020 | 12.4% |
| PROTHENA ORD | 20 | Q3 2023 | 28.0% |
| IRONWOOD PHARMA CL A ORD | 20 | Q1 2020 | 13.9% |
| GALAPAGOS NV SPON ADR | 19 | Q3 2023 | 12.0% |
| MORPHIC HOLDING ORD | 18 | Q3 2023 | 8.5% |
| ARCUS BIOSCIENCES ORD | 17 | Q1 2022 | 7.1% |
| ANAPTYSBIO INC | 16 | Q3 2023 | 8.3% |
View EcoR1 Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Mersana Therapeutics, Inc. | July 27, 2023 | 19,364,688 | 16.9% |
| TScan Therapeutics, Inc. | June 05, 2023 | 5,000,000 | 11.7% |
| 2seventy bio, Inc. | February 14, 2023 | 1,143,494 | 3.0% |
| Avidity Biosciences, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Surface Oncology, Inc. | February 13, 2023 | 3,924,713 | 6.5% |
| Akouos, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Alector, Inc. | February 10, 2023 | 4,056,548 | 4.9% |
| Arcus Biosciences, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Gritstone bio, Inc.Sold out | February 10, 2023 | 0 | 0.0% |
| Ovid Therapeutics Inc. | February 10, 2023 | 6,117,400 | 8.7% |
View EcoR1 Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-03 |
| SC 13G/A | 2024-04-08 |
| 3 | 2024-03-26 |
| SC 13G/A | 2024-03-26 |
| SC 13G | 2024-03-11 |
| SC 13D | 2024-02-22 |
| SC 13G | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View EcoR1 Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.